• 1. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 2. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 3. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 4. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 5. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119

Introduction to 2-(4-Iodo-1H-pyrazol-1-yl)acetamide (CAS No. 1217862-55-9)

2-(4-Iodo-1H-pyrazol-1-yl)acetamide is a significant compound in the realm of pharmaceutical chemistry, characterized by its unique structural and functional properties. This compound, identified by the Chemical Abstracts Service Number (CAS No.) 1217862-55-9, has garnered attention due to its potential applications in drug discovery and medicinal chemistry. The presence of both an iodo substituent and a pyrazole ring in its molecular structure imparts distinct reactivity and biological activity, making it a valuable scaffold for further chemical modifications and biological evaluations.

The pyrazole moiety is a heterocyclic aromatic compound that is widely recognized for its role in various pharmacological activities, including anti-inflammatory, antimicrobial, and anticancer properties. The introduction of an iodine atom at the 4-position of the pyrazole ring enhances its utility as a synthetic intermediate, facilitating further functionalization through cross-coupling reactions such as Suzuki-Miyaura or Stille couplings. These reactions are pivotal in constructing more complex molecular architectures, which can lead to the development of novel therapeutic agents.

The acetamide functional group in 2-(4-Iodo-1H-pyrazol-1-yl)acetamide contributes to its solubility and metabolic stability, which are critical factors in drug design. The amide bond not only serves as a site for further derivatization but also influences the compound's pharmacokinetic profile. Recent studies have highlighted the importance of amide-based molecules in achieving optimal bioavailability and target specificity. The combination of these structural features makes 2-(4-Iodo-1H-pyrazol-1-yl)acetamide a promising candidate for exploring new therapeutic avenues.

In the context of contemporary pharmaceutical research, 2-(4-Iodo-1H-pyrazol-1-yl)acetamide has been investigated for its potential role in modulating various biological pathways. The pyrazole ring is known to interact with enzymes and receptors involved in inflammation and cancer progression. For instance, derivatives of pyrazole have shown inhibitory effects on kinases and other enzymes that are aberrantly activated in tumor cells. The iodo substituent further enhances the compound's ability to participate in selective binding interactions, thereby improving target engagement.

Recent advancements in medicinal chemistry have leveraged computational methods to predict the binding affinity and pharmacological activity of 2-(4-Iodo-1H-pyrazol-1-yl)acetamide. Molecular docking studies have revealed that this compound can effectively interact with proteins such as kinases and transcription factors, which are key targets in oncology research. The ability to fine-tune the structure through selective modifications allows researchers to optimize potency while minimizing off-target effects. This approach aligns with the growing emphasis on precision medicine, where tailored therapeutic strategies are designed to address specific disease mechanisms.

The synthesis of 2-(4-Iodo-1H-pyrazol-1-yl)acetamide involves multi-step organic transformations that highlight the compound's synthetic versatility. Key steps include the preparation of the pyrazole core, followed by iodination and subsequent coupling with acetamide derivatives. These synthetic routes are well-documented in the literature and have been optimized for scalability and reproducibility. The availability of high-quality starting materials ensures that researchers can efficiently produce sufficient quantities for both preclinical studies and industrial applications.

From a regulatory perspective, 2-(4-Iodo-1H-pyrazol-1-yl)acetamide must comply with stringent quality control measures to ensure safety and efficacy. Analytical techniques such as nuclear magnetic resonance (NMR) spectroscopy, high-performance liquid chromatography (HPLC), and mass spectrometry (MS) are employed to confirm its identity and purity. These methods provide detailed insights into the compound's molecular structure and chemical properties, which are essential for meeting regulatory standards set by agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

The potential applications of 2-(4-Iodo-1H-pyrazol-1-yl)acetamide extend beyond oncology research. Its structural features make it a versatile building block for developing compounds targeting neurological disorders, infectious diseases, and metabolic conditions. For example, pyrazole derivatives have been explored for their antiviral properties, particularly against RNA viruses such as influenza A virus. The iodo substituent allows for further derivatization into compounds that can inhibit viral replication or modulate host immune responses.

In conclusion, 2-(4-Iodo-1H-pyrazol-1-yl)acetamide (CAS No. 1217862-55-9) represents a significant advancement in pharmaceutical chemistry due to its unique structural attributes and broad applicability. Its role as a synthetic intermediate enables the development of novel therapeutics targeting various diseases, including cancer and infectious disorders. As research continues to uncover new biological functions associated with pyrazole-based compounds, 2-(4-Iodo-1H-pyrazol-1-yI)acetamide is poised to play a crucial role in future drug discovery efforts.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)